Telitacicept Shows Lasting Symptom Control in Myasthenia Gravis Trial
A 48-week study found more than 94% of participants achieved significant symptom improvement, signaling a potential advance in treating the rare neuromuscular disease.
A clinical trial of telitacicept in generalized myasthenia gravis demonstrated deep and sustained symptom control through 48 weeks, with more than 94% of participants achieving at least a five-point improvement on the MG-ADL scale, a standard measure of how the disease affects daily activities.
The MG-ADL, or Myasthenia Gravis Activities of Daily Living scale, tracks a patient's ability to perform routine tasks such as chewing, swallowing, breathing, and brushing teeth. A five-point or greater reduction is widely considered a clinically meaningful threshold, indicating that patients experienced a substantial easing of disease burden over the study period.
Read more MSIG USA Names Oscar Aguilar to Lead Excess and Surplus Property →
Telitacicept is a dual-target biologic that inhibits BLyS and APRIL, two proteins involved in the survival and maturation of B cells and plasma cells, which play a central role in the autoimmune attack underlying myasthenia gravis. Researchers described the results as reflecting both the depth and durability of the treatment's effect across the full trial duration.
Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder in which the immune system mistakenly attacks proteins at the junction between nerves and muscles, leading to weakness and fatigue. The condition affects an estimated 36,000 to 60,000 people in the United States, and existing therapies do not provide adequate long-term control for all patients, leaving a recognized unmet need in the field.
The trial results add to a growing body of evidence evaluating telitacicept across autoimmune indications. Continue reading at GlobeNewswire - Industry News on Financial Services.
